MAP1LC3A and fatty liver disease: Both expression of MAP1LC3A and Beclin 1 in patient is exhibited much lower in immunostaining (Fig. 8A m–q, B) and Western blotting (Fig. 8D) but not vanished indicating possible tendency of lipophagy in development of fatty liver disease.